FDA Approves Camzyos for the Treatment of Obstructive Hypertrophic Cardiomyopathy

What Is Obstructive Hypertrophic Cardiomyopathy?

Hypertrophic cardiomyopathy, commonly shortened to HCM, is a disease in which the heart muscle becomes abnormally thick. It is frequently inherited, although the severity, symptoms, and age at which it appears can differ dramaticallyeven among members of the same family.

In obstructive HCM, the thickened muscle, often involving the wall between the heart’s ventricles, narrows the route through which blood leaves the left ventricle. This route is called the left ventricular outflow tract, or LVOT. When the heart contracts forcefully, the obstruction can become more pronounced, making it harder to deliver blood efficiently to the body.

Common symptoms include shortness of breath, fatigue, chest pain, dizziness, fainting, heart palpitations, and difficulty exercising. Some people feel relatively comfortable while resting but become breathless after climbing stairs, carrying groceries, or attempting a brisk walk. In other words, the heart may look enthusiastic on paper while the patient feels as though someone quietly replaced the staircase with a mountain.

What Do NYHA Classes II and III Mean?

The New York Heart Association classification system describes how much heart-related symptoms limit physical activity. People in class II generally have mild limitations: they are comfortable at rest, but ordinary activity may cause fatigue, palpitations, or shortness of breath. People in class III have more substantial limitations, with symptoms occurring during less-than-ordinary activity.

Camzyos was initially approved specifically for symptomatic adults in these two categories. It has not been established as safe and effective in pediatric patients, and it should not be viewed as a casual treatment for every person with a thickened heart muscle. Accurate diagnosis matters because other diseases, including cardiac amyloidosis and certain storage disorders, can resemble HCM but require different treatment strategies.

How Camzyos Works

Camzyos is a cardiac myosin inhibitor. Myosin is one of the key proteins that allows heart-muscle fibers to contract. In obstructive HCM, too many myosin heads may participate in force-producing interactions with actin, contributing to excessive contraction, impaired relaxation, and LVOT obstruction.

Mavacamten allosterically modulates cardiac myosin, reducing the number of actin-myosin cross-bridges that generate force. The result is a more controlled contraction and less obstruction to blood leaving the heart.

A useful comparison is a crowded doorway. The solution is not to tell everyone to push harder. The solution is to reduce the pileup so people can move through the opening more efficiently. Camzyos attempts something similar at the molecular level, although cardiology naturally uses fewer elbows and considerably more echocardiography.

This targeted mechanism distinguished mavacamten from traditional HCM medications. Beta blockers and nondihydropyridine calcium channel blockers can reduce symptoms by slowing the heart or decreasing contractility, but they were not developed specifically to regulate cardiac myosin. Camzyos became the first FDA-approved medication in its class and opened a new therapeutic category for obstructive HCM.

The Clinical Trial Behind FDA Approval

The pivotal evidence came primarily from EXPLORER-HCM, a phase 3, double-blind, randomized, placebo-controlled trial involving 251 adults with symptomatic NYHA class II or III obstructive HCM. Participants had an ejection fraction of at least 55% and an LVOT gradient of at least 50 mm Hg at rest or when the obstruction was provoked.

Participants were assigned to receive either Camzyos or placebo once daily for 30 weeks. There were 123 patients in the Camzyos group and 128 in the placebo group. Doses were adjusted according to treatment response, LVOT gradient, drug exposure, and left ventricular ejection fraction.

The Primary Result

The trial’s primary endpoint combined changes in peak oxygen consumption with changes in NYHA functional class. At week 30, 37% of patients taking Camzyos met this endpoint, compared with 17% of patients receiving placebo. That represented an adjusted treatment difference of approximately 19 percentage points.

The endpoint was deliberately demanding. Participants needed either a meaningful improvement in peak oxygen consumption accompanied by an improvement in NYHA class, or a larger improvement in oxygen consumption without worsening of their functional class. This was not simply a “Do you feel somewhat better?” survey conducted beside the hospital vending machine. It combined objective exercise measurements with clinically relevant changes in symptoms.

Improvements Beyond the Primary Endpoint

Camzyos also produced significant improvements across several secondary outcomes. Sixty-five percent of treated patients improved by at least one NYHA class, compared with 31% of patients receiving placebo. The average post-exercise LVOT gradient declined by 47 mm Hg in the Camzyos group, versus a 10 mm Hg reduction with placebo.

Peak oxygen consumption improved by an average of 1.4 mL/kg/min with Camzyos while remaining essentially unchanged in the placebo group. Patient-reported health status and shortness-of-breath scores also favored treatment. A separate analysis found a clinically meaningful improvement in Kansas City Cardiomyopathy Questionnaire scores, including improvements in symptoms, physical function, and quality of life.

Cardiac imaging analyses further suggested favorable changes in measures such as left ventricular mass and left atrial volume. These findings are scientifically interesting, but they should not be translated into a claim that the medication permanently reverses HCM. The FDA label notes that the clinical significance of some structural and biomarker changes remains uncertain.

Camzyos Safety and the Boxed Warning

The same mechanism that makes Camzyos useful also creates its most important risk. By reducing cardiac contraction, the medication can lower left ventricular ejection fraction too far and cause heart failure due to systolic dysfunction.

For that reason, Camzyos carries an FDA boxed warning. An echocardiogram is required before treatment and at designated intervals during therapy. Starting or increasing the medication is not recommended when the ejection fraction is below 55%. Treatment must be interrupted if ejection fraction falls below 50%, if heart-failure symptoms develop, or if the patient’s clinical condition worsens.

The CAMZYOS REMS Program

Camzyos is distributed through a Risk Evaluation and Mitigation Strategy, or REMS, program. Prescribers, patients, and dispensing pharmacies must participate in the program, and patients must complete the required cardiac monitoring.

This restricted system is not merely decorative paperwork wearing a medical badge. It is intended to ensure that treatment pauses, dose adjustments, echocardiograms, and medication-interaction checks occur before excessive drug exposure harms the heart.

The FDA approved several REMS and labeling updates in April 2025. Among other changes, stable patients in the maintenance phase may undergo echocardiographic monitoring every three to six months rather than every 12 weeks. Eligible patients beyond their first year of therapy may also receive up to a 90-day supply. Monitoring remains mandatory; the updated system simply reduces some of the burden for patients who have achieved a stable dose and response.

Drug Interactions Require Serious Attention

Mavacamten is metabolized primarily through CYP2C19 and, to a lesser degree, CYP3A4 and CYP2C9. Medications that inhibit these enzymes can raise mavacamten exposure, increasing the risk of systolic dysfunction. Enzyme inducers can lower exposure and reduce effectiveness; abruptly discontinuing an inducer can then cause mavacamten levels to rise.

Strong CYP2C19 inhibitors and moderate-to-strong CYP2C19 or CYP3A4 inducers are contraindicated. Other inhibitors may require a lower Camzyos dose, a temporary interruption, extra monitoring, or a different starting dose. The April 2025 label update removed blanket contraindications for certain moderate CYP2C19 inhibitors and strong CYP3A4 inhibitors, replacing them with more detailed management instructions.

Patients should discuss every prescription, supplement, herbal product, and over-the-counter medicine with their treatment team. Even common acid-reducing medicines such as omeprazole, esomeprazole, or cimetidine can matter. Grapefruit products may also affect treatment. The innocent-looking heartburn pill deserves a seat at the medication-review meeting.

Other Side Effects and Pregnancy Precautions

In EXPLORER-HCM, the most common adverse reactions occurring more frequently with Camzyos than placebo were dizziness, reported by 27% versus 18%, and syncope, reported by 6% versus 2%. Seven Camzyos-treated patients experienced a reversible reduction in ejection fraction below 50%; their ejection fraction recovered after treatment interruption.

Based on animal data, Camzyos may cause fetal harm. Pregnancy should be ruled out before treatment in patients who can become pregnant, and effective contraception is advised during therapy and for four months after the final dose. Because mavacamten can reduce the effectiveness of certain hormonal contraceptives, the treatment team should provide individualized contraceptive guidance.

Where Camzyos Fits in Modern HCM Treatment

Camzyos did not make beta blockers, calcium channel blockers, septal myectomy, or alcohol septal ablation disappear. Instead, it added an important option for adults who remain symptomatic despite first-line therapy or who need another approach before considering an invasive procedure.

The 2024 American Heart Association and American College of Cardiology HCM guideline incorporated cardiac myosin inhibitors as a treatment option for patients with symptomatic obstructive disease who do not obtain adequate relief from first-line medication. Experienced HCM centers remain especially valuable when symptoms persist, the diagnosis is uncertain, an invasive procedure is being considered, or the patient has complex arrhythmia or sudden-death risk factors.

The VALOR-HCM trial examined patients with severe symptoms who had already been referred for septal reduction therapy. Results showed that mavacamten reduced the proportion who remained eligible for or proceeded to septal reduction at studied follow-up points. This does not mean surgery has become obsolete. Septal myectomy can provide substantial and durable relief when performed at an experienced center, and treatment decisions should reflect anatomy, age, other medical conditions, personal priorities, access, and long-term preferences.

Camzyos Is Symptom Therapy, Not a Complete HCM Management Plan

Mavacamten does not eliminate the need to assess atrial fibrillation, stroke risk, ventricular arrhythmias, family history, genetic counseling, or sudden cardiac death risk. It also does not replace discussions about exercise, pregnancy planning, implantable defibrillators, or screening of close relatives.

A patient may achieve an excellent reduction in LVOT obstruction and still need ongoing rhythm monitoring or other preventive care. HCM has several moving parts, and unfortunately none of them comes with a convenient “skip tutorial” button.

What Patients Should Discuss Before Starting Camzyos

• Whether the diagnosis is confirmed as symptomatic obstructive HCM rather than another cause of heart-muscle thickening.
• The current LVOT gradient, ejection fraction, NYHA class, and major treatment goals.
• All prescription drugs, over-the-counter medicines, vitamins, herbal products, and grapefruit consumption.
• The required echocardiogram schedule and what happens when an appointment is delayed.
• Symptoms that should trigger an urgent call, including new shortness of breath, chest discomfort, swelling, rapid weight gain, palpitations, or unusual fatigue.
• Pregnancy plans, contraception, insurance authorization, specialty-pharmacy delivery, and REMS enrollment.

Camzyos dosing is individualized. The usual starting dose is 5 mg once daily, with available doses of 2.5 mg, 5 mg, 10 mg, and 15 mg. Some patients taking interacting medications may require a different starting dose or dose adjustment. Patients should never increase, reduce, interrupt, or restart Camzyos without specific instructions from their clinician.

What the FDA Approval Changed

The Camzyos approval represented more than another capsule entering an already crowded pharmacy shelf. It demonstrated that researchers could translate decades of work on sarcomere biology into a medication targeting a central mechanism of obstructive HCM.

Long-term extension studies have continued to examine durability and safety. Interim findings from MAVA-LTE and PIONEER-OLE suggest that improvements in symptoms, LVOT gradients, functional class, and patient-reported health status can persist during longer treatment. However, these studies include smaller populations or open-label follow-up, so ongoing surveillance and real-world evidence remain important.

The larger lesson is that targeted therapy can substantially improve daily function without pretending that one medication solves every aspect of a complicated genetic heart disease. Camzyos expanded the treatment menu. It did not fire the cardiologist, retire the echocardiogram machine, or grant anyone permission to ignore a suspicious new symptom.

Practical Experience: What a Camzyos Treatment Journey May Feel Like

The following is an illustrative care experience rather than a personal testimonial. Individual responses, timelines, monitoring schedules, and insurance processes vary.

Before the First Dose

The treatment experience usually starts with more preparation than patients expect. There may be a confirming echocardiogram, a detailed medication review, REMS enrollment, insurance authorization, and coordination with a certified specialty pharmacy. Patients who expected to leave the office holding a prescription may instead leave with a checklist impressive enough to qualify as light weekend reading.

This preparation can feel frustrating, especially for someone already tired or short of breath. Still, each step addresses a genuine safety issue. The baseline echocardiogram establishes whether the heart is contracting strongly enough to begin therapy. The medication review identifies products that could dramatically alter mavacamten exposure. The specialty pharmacy verifies authorization before dispensing the medication.

The Early Monitoring Period

During the first several weeks, treatment may feel less like “take one capsule and forget about it” and more like a carefully supervised experiment. Follow-up echocardiograms measure ejection fraction and LVOT gradient. The dose may remain unchanged, decrease, increase, or pause depending on the results.

Patients may be tempted to judge success after a few days, but mavacamten has a long and variable half-life. It accumulates gradually, and changes in dosage take time to reach their full effect. Some patients notice improved breathing or stamina relatively early, while others improve slowly or require multiple dose assessments.

Changes in Everyday Life

Meaningful improvement does not always arrive as a dramatic movie scene with inspirational music. It may appear as reaching the mailbox without stopping, taking a shower without needing to sit down, walking through a grocery store, carrying laundry, or finishing a conversation without becoming breathless.

These small victories matter because functional limitations often shape a patient’s entire day. Reduced symptoms may make social activities, work, exercise, and family responsibilities easier. At the same time, feeling better does not mean monitoring can stop. Ejection fraction may decline without obvious early symptoms, which is why echocardiograms remain part of the treatment rather than an optional bonus feature.

Living With the Medication Rules

One of the most important habits is checking before starting or stopping another medicine. A patient with a respiratory infection, for example, should not assume that a new antibiotic, antifungal drug, or over-the-counter remedy is automatically compatible with Camzyos. The prescribing cardiologist, pharmacist, or REMS team may need to review it first.

Travel also requires planning. Patients may need to coordinate medication delivery, protect the capsules from inappropriate storage conditions, and schedule echocardiograms around trips. A missed capsule generally should be taken later that same day when remembered, without doubling the next dose, but individualized instructions from the treating team take priority.

The Long-Term Perspective

After a stable dose is established, the process may become less demanding. Monitoring intervals can lengthen for eligible patients, and longer prescription supplies may reduce delivery hassles. Nevertheless, treatment remains an ongoing partnership rather than a one-time repair.

Patients should continue reporting changes in stamina, swelling, breathing, heart rhythm, chest symptoms, weight, and overall health. Treatment goals should also be revisited. For one person, success may mean returning to work. For another, it may mean avoiding or delaying an invasive procedure. Someone else may prefer septal myectomy because it offers a procedural solution rather than indefinite medication and monitoring.

The best experience is not defined by choosing the newest therapy. It is defined by matching the treatment to the patient’s disease, priorities, risks, and daily life through informed shared decision-making.

Conclusion

The FDA approval of Camzyos marked a major advance for adults with symptomatic NYHA class II or III obstructive hypertrophic cardiomyopathy. By directly modulating cardiac myosin, mavacamten can reduce LVOT obstruction, improve exercise capacity, and relieve symptoms for appropriately selected patients.

Its benefits come with substantial responsibilities. Echocardiographic monitoring, REMS participation, careful dose adjustment, pregnancy precautions, and rigorous screening for drug interactions are essential. Camzyos is not a universal cure, but for many eligible patients it offers something highly valuable: a targeted opportunity to breathe more easily, move more comfortably, and reclaim activities that obstructive HCM had quietly taken away.